Application of a Glycoproteomics-Based Biomarker Development Method: Alteration in Glycan Structure on Colony Stimulating Factor 1 Receptor as a Possible Glycobiomarker Candidate for Evaluation of Liver Cirrhosis

• Published in: Journal of proteome research Vol. 13; no. 3; pp. 1428 - 1437
• Main Authors: Ocho, Makoto, Togayachi, Akira, Iio, Etsuko, Kaji, Hiroyuki, Kuno, Atsushi, Sogabe, Maki, Korenaga, Masaaki, Gotoh, Masanori, Tanaka, Yasuhito, Ikehara, Yuzuru, Mizokami, Masashi, Narimatsu, Hisashi
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 07.03.2014
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers - blood; Carbohydrate Conformation; Enzyme-Linked Immunosorbent Assay; Feasibility Studies; Female; Glycoproteins - blood; Glycoproteins - chemistry; Hepatitis B, Chronic - blood; Hepatitis C, Chronic - blood; Humans; Liver Cirrhosis - blood; Liver Cirrhosis - diagnosis; Male; Middle Aged; Plant Lectins - chemistry; Polysaccharides - analysis; Polysaccharides - chemistry; Protein Array Analysis; Proteomics; Receptor, Macrophage Colony-Stimulating Factor - blood; Receptor, Macrophage Colony-Stimulating Factor - chemistry; Receptors, N-Acetylglucosamine - chemistry; glycan alteration; glycoproteomics; glycobiomarker; glycoprotein; colony stimulating factor 1 receptor; lectin array; liver cirrhosis
• ISSN: 1535-3893; 1535-3907
• DOI: 10.1021/pr400986t

The importance of diagnosis and therapies for liver cirrhosis (LC) is indisputable. Thus, a reliable method for monitoring the progression of liver fibrosis and resultant LC is urgently needed. Previously, using a lectin-assisted glycoproteomic method, we identified 26 serum glycoproteins as promising glycobiomarker candidates for monitoring the progression of liver diseases. In this study, we identified colony stimulating factor 1 receptor (CSF1R) as a promising LC marker candidate and then established Wisteria floribunda agglutinin (WFA)-reactive CSF1R (WFA+-CSF1R) as a novel possible glycobiomarker candidate by utilizing a glycoproteomics-based strategy. The serum level of WFA+-CSF1R in patients with hepatitis C virus (HCV)-infected liver disease was measured by an antibody-lectin sandwich ELISA. In a proof-of-concept experiment of the strategy preceding to future clinical studies, LC patients showed a high serum WFA+-CSF1R level in selected samples (P = 1.3 × 10–17). This result suggests WFA+-CSF1R is a possible biomarker candidate for evaluation of LC. Our results verified feasibility of this strategy for glycobiomarker development.